Kornimate/medical-research-clean huggingface dataset:
ultrasound elastography in imaging patients with thyroid nodules

Conditions: Malignant Thyroid Gland Neoplasm; Thyroid Gland Nodule

Summary: this clinical trial studies how well ultrasound elastography works in assessing the cancer status of potentially malignant thyroid nodules.

primary objectives: determine the utility of ultrasound elastography in evaluation of thyroid nodules being evaluated for the presence of cancer. elastography measures the passages of ultrasound shear waves through tissue to gauge the stiffness and compressibility of the tissue, collectively "tissue stiffness," and may be a better way to image thyroid nodules. tissue stiffness is a physiological parameter that is being evaluated for differences between non-cancerous (benign) and cancerous thyroid nodules. participants will undergo elastography over the 10 minutes prior to either fine needle aspiration of a biopsy specimen or surgical resection of the thyroid nodule. tissue specimens from the biopsy specimen or surgical resection will be assessed pathologically to determine actual cancer status.

Eligibility criteria:
inclusion criteria: * presence of a thyroid nodule that is amenable to ultrasound guided fine needle aspiration exclusion criteria: * patients who are unable to lie supine for a biopsy * pregnant patients
prevalence of egfr mutations in epidermoïd bronchopulmonary cancers in réunion island

Conditions: Squamous Cell Lung Cancer

Summary: lung cancer is the most common cancer in the world with 1.8 million estimated incident cases in 2012 (12.9% of diagnosed cancers) and 1.6 million deaths annually. in mainland france, lung cancer represents 12% of all incident cancers. the standardized incidence rates for the world population were then 52.6 per 100,000 for men and 23.4 / 100,000 for women, respectively. in reunion, 415 cases of primary bronchopulmonary cancers were reported for the years 2011-2012, which gives standardized incidence rates lower than those observed in mainland france (33.1 / 100,000 in humans, 8.2 / 100,000 in women). if the incidence of bronchopulmonary cancer is lower in réunion than in mainland france, the study of histological subtypes appears different: the investigators observe a greater frequency of adenocarcinomas (65% vs 45%), at the expense squamous cell carcinomas. in addition, for adenocarcinomas, the frequency of egfr type mutations is twice as high (23% vs 11%). thus, if this rate of egfr mutations observed in mainland france is very close to those described in all caucasian populations, that observed in the reunionese population appears closer to those described in asian populations, and more particularly the indian population. this can perhaps be explained by the fact that the population of reunion is a cosmopolitan and highly mixed race, whose share of asian origin, mainly indian and chinese, is significant. in clinical practice, inca recommends carrying out the search for the egfr mutation for any patient with locally advanced or metastatic lung carcinoma, not small cell and non epidermoid. this restriction to the histology of adenocarcinoma is justified by the low frequency of egfr mutations for other histological types in caucasian populations. however, some studies describe significant egfr mutation rates for epidermoid cancers in asian populations, particularly in india. thus, given that a large part of the réunion population shares asian origins, the question of the frequency of egfr mutations among squamous cell carcinomas in réunion is asked. the hypothesis of this research is that, given the ethnic characteristics of the reunionese population, the proportion of bronchopulmonary epidermoid cancers carrying the egfr mutation is potentially significantly higher than that observed in caucasian populations, including the french metropolitan population. if this rate of egfr mutations were high in the reunion population, it would then be necessary to allow the search for this mutation to be extended to all bronchopulmonary cancers, which will improve their therapeutic management.


Eligibility criteria:
inclusion criteria: * aged 18 and over, * who is diagnosed with bronchopulmonary squamous cell carcinoma in one of the 2 anatomopathology laboratories at reunion university hospital, exclusion criteria: - refuses to participate in the study
a study of ssgj-613 in gout subjects initiating urate-lowering treatment.

Conditions: Gout Arthritis

Summary: the purpose of this study is to determine the efficacy and safety of recombinant anti-interleukin-1β humanized monoclonal antibody injection in chinese gout participants initiating urate-lowering treatment.


Eligibility criteria:
inclusion criteria: * must be 18 years to 75 years, both male and female. * bmi ≤40 kg/m2. * meeting the american college of rheumatology (acr) 2015 criteria for the classification of gouty arthritis. * ≥2 acute gout flares within 1 year prior to screening. * willingness to initiate urate-lowering treatment or to initiate urate-lowering treatment within 7 days prior to administration. exclusion criteria: * gout caused by radiotherapy/chemotherapy, organ transplantation, tumors, etc. * evidence/suspicion of infectious/septic arthritis, or other acute inflammatory arthritis. * presence of severe renal function impairment. * intolerance of subcutaneous injection. * known presence or suspicion of active or recurrent bacterial, fungal, or viral infection at the time of enrollment. * live vaccinations within 8 weeks prior to the start of the study. * use of forbidden therapy
risk stratification using meessi-ahf scale in ed and impact on ahf outcomes

Conditions: Acute Heart Failure; Emergencies

Summary: evaluate the impact the application of the messi-ahf scale (a risk stratification scale specifically derived and validated in patients diagnosed with acute heart failure, ahf) in decision making (admission vs. discharge) by emergency physicians in emergency departments (ed) and its potential impact on on the short-term prognosis of patients with ahf.

study 1: a non-intervention study involving the consecutive inclusion of 3,200 patients with ahf in 16 spanish eds managed according to the usual practice. individual risk will be retrospectively stratified according to the meessi-ahf scale, and we will analyze the distribution of the categories of risk in patients admitted and discharged and the prognosis of patients with low risk discharged from the ed and compare the events observed in this subgroup of patients with the recommended international standards. study 2: this is a cuasiexperimental study in 8 eds with consecutive inclusion of 1,600 patients with ahf managed according to the usual practice (without stratification of risk, pre-phase) and 1,600 patients managed after the implementation of the meessi-ahf scales for risk stratification before the final decision making in the ed (post-phase). if the patient has low risk the calculator will propose discharge; for the remaining categories of risk the calculator will propose patient admission. the final decision corresponds to the attending physician and if this decision differs from what was proposed, a reason will be given. study 3: open multicentre (8 eds) randomized clinical trial (1:1) comparing the results obtained in the patients randomized to usual clinical practice (1,600 patients) with those obtained in the patients randomized to the use of the meessi-ahf scale for risk stratification (1,600 patients) prior to decision making. the dynamics of the decision proposed by the scale will be the same as that in study 2. main outcomes (studies 1, 2, 3): death (by any cause and cardiovascular cause) at 30 days and at 1 year; combined event (revisit to the ed or hospitalization for ahf or death) at 30 days post-discharge (global analysis of all the patients with ahf stratified by categories of risk); days alive and outside the hospital at 30 days after the index event (consultation to the ed); and proportion of patients managed without hospitalization.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of ahf based on framinham criteria * nt-probnp \>300 pg/ml * patient able to consent exclusion criteria: * st-elevation acute coronary syndrome
pilot study "ahsp as a biomarker of sickle cell disease in a population of adults and children"

Conditions: in Relation to Sickle Cell Disease

Summary: evaluation of ahsp concentration in total blood as a biomarker in adult and pediatric sickle cell patients

research involving non-interventional humans. selection and inclusion of patients by chsd investigators. collection of clinical data by investigators and chsd urc staff. biochemical and hematological measurements by the chsd medical biology laboratory for "care" samples pseudonymization of 4 ml "research" samples by the urc then fractionation of the samples by 1 ml, and storage at -80°c within the medical biology laboratory of the chsd. transport of samples at -80°c to team 1 of dr baudin-creuza (créteil). preparation of genomic dna from a 1 ml fraction then α and β globin genotyping by dr pissard. measurement of the ahsp concentration from the other fractions. comparison of the ahsp concentration according to the group of subjects, and with the different parameters, then correlation analysis

Eligibility criteria:
inclusion criteria: inclusion criteria for sickle cell patients 1. adults: \> 15 years and 6 months 2. pediatrics: ≥ 3 years and ≤ 15 years and 6 months 3. known ss or sβ0 phenotypes inclusion criteria for control patients. 1 -adults: \> 15 years and 6 months /pediatrics: ≥ 3 years and ≤ 15 years and 6 months 2-absence of hemoglobinopathy 3-follow-up for one of the following conditions (adults): evaluation of hematological disease excluding hemoglobinopathy, evaluation of prolonged fever or inflammatory syndrome, initial or episodic evaluation of an auto-inflammatory disease or systemic disease, general health deterioration -follow-up for one of the following conditions (pediatrics): suspected precocious puberty, growth delay, or neurodevelopmental disorder 4-blood sample planned as part of medical care exclusion criteria: 1. hemoglobin disorder other than sickle cell disease (criteria for sickle cell patients) 2. hemoglobinopathies other than sickle cell disease (criteria for control patients) 3. transfusion less than 3 months ago 4. chronic active viral disease: hepatitis b, c, hiv 5. current infections or known inflammatory pathologies 6. known hyper or hypothyroidism or subject treated with levothyroxine 7. active tumor pathology or remission for less than 5 years 8. oral corticosteroid therapy in progress 9. participation in interventional biomedical research 10. opposition to participation in research by the patient if he is an adult, or by one of the two parents if the patient is a minor. 11. non-affiliation to a social security system

Keywords: ahsp sickle cell disease ss phenotype sβ0 phenotype
effects of grade iii traction-mobilization in end-range joint position in patients with hip osteoarthritis

Conditions: Osteoarthritis, Hip

Summary: lower limb osteoarthritis is a major health problem in the westernized countries. the current gold standard treatment is joint replacement. however clinical guidelines recommend physical therapy as first option for these patients. manual therapy has reported good reports in function, range of motion and pain in patients with hip osteoarthritis. the main aim of this study is to test the effects of a manual therapy protocol based on manual traction mobilization of the hip joint in an end range position and compare them with the effects achieve with the same protocol based on manual traction mobilization of the hip joint in a resting position. the investigators will use the caudal traction mobilization described by kaltenborn. the study will test the effects of both treatments in passive range of motion, function and pain after three weeks of treatment, three weeks after finalizing the treatment and six weeks after.


Eligibility criteria:
inclusion criteria: * hip osteoarthritis diagnosis * diminished range of motion * sign the informed consent exclusion criteria: * contraindications to manual therapy. * sensitivity impairments in low back, pelvis, knee or foot regions. * being involved in other physical therapy treatments * to change medication use during the study
evaluate patients with chronic hepatitis by three-dimensional force-controlled ultrasound measurement

Conditions: Fatty Liver

Summary: ultrasound (us) b mode image is an alternative method to measure tissue structure and has proven to be an accurate technique to measure subcutaneous fat thickness. however, pressing the transducer onto the skin with too much force will significantly reduce the subcutaneous adipose tissue thickness. in this study, a force controlled system combined with us transducer was used for 3d subcutaneous fat imaging and reconstruction.

the diagnosis of fatty liver (steatosis) is made when fat in the liver exceeds 5-10% by weight. fatty liver (fl) is commonly associated with alcohol or metabolic syndrome (diabetes, hypertension, obesity, and dyslipidemia), but can also be due to any one of many causes. most people were detected from serum lipid abnormalities in the physical examination, and confirmed as the fatty liver disease by ultrasound imaging. in some previous studies, ultrasound was reported to provide an accurate and reliable measurement tool for the thickness measurements of subcutaneous adipose tissue. this method can overcome some limitations of the skinfold thickness measurements. ultrasound (us) b mode image is an alternative method to measure tissue structure and has proven to be an accurate technique to measure subcutaneous fat thickness. however, pressing the transducer onto the skin with too much force will significantly reduce the subcutaneous adipose tissue thickness. in this study, a force controlled system combined with us transducer was used for 3d subcutaneous fat imaging and reconstruction. finally, the correlations between body fat percentage and subcutaneous fat in steatosis patients have been investigated. the body fat percentage was determined by dual energy x-ray absorptiometry (dexa, ge lunar idxa canner) and bioelectrical impedance analysis (bia, omron，hbf-370), and then, the correlation between body fat percentage and subcutaneous adipose tissue in normal and steatosis patients have been evaluated.

Eligibility criteria:
inclusion criteria: * aged between 20-65 adults who are confirmed have fatty liver by echo exclusion criteria: * none
a single-dose pilot study of radiolabeled amatuximab (morab-009) in mesothelin over expressing cancers

Conditions: Mesothelioma; Pancreatic Cancer; Ovarian Cancer; Non-small Cell Lung Cancer

Summary: this research is being conducted to determine the biodistribution of radiolabeled amatuximab in tumor and non-tumor tissues in subjects with mesothelin over expressing cancer including mesothelioma, pancreatic, ovarian or non small cell lung cancer.

the primary objective is to determine the biodistribution of radiolabeled amatuximab in tumor and nontumor tissues in subjects with mesothelin over-expressing cancers including mesothelioma, pancreatic, ovarian, and non small cell lung cancer. this is a single-center, single-dose, open-label, pilot study of amatuximab in approximately 20 subjects with mesothelin expressing tumors. 111indium-radiolabeled amatuximab (5 mci) will be administered. serial spect imaging (at 3 specific time points up to 196 hours after cold infusion) will be performed to determine binding to tumor and nontumor tissue. subjects will be observed closely for safety and possible development of anti-amatuximab antibodies. pharmacokinetics of radiolabeled antibody will be determined with imaging over time.

Eligibility criteria:
inclusion criteria: * female and male subjects \> or = 18 years of age * histologically confirmed mesothelin-expressing cancer * measurable disease that has progressed through prior therapy and that includes a non-hepatic lesion for imaging that is \> or = 1.5cm, as defined by recist v1.1 and disease location, at discretion of the physician, or evaluable by clinical symptoms supported by biomarker, radiological or pathological studies conducted within 4 weeks prior to study entry exclusion criteria: * known allergy or hypersensitivity to monoclonal antibodies * known to develop haca * prior treatment with amatuximab * prior treatment with ss1 (dsfv)pe38 (ss1p) * prior treatment with another test article within previous 30 days * known brain metastasis * known prosthetic devices that would prohibit imaging ow lesion of interest due to radiographic artifact * chemotherapy, biological therapy, radiation therapy or immunotherapy within 3 weeks prior to dosing with amatuximab
traumatic brain injury feasibility study (epic-011)

Conditions: Traumatic Brain Injury; Controls

Summary: the purpose of this research study is to evaluate whether data made by the clearview system can be used to detect whether someone has a traumatic brain injury and how severe the injury is.

traumatic brain injury (tbi) is a significant cause of death and disability in the u.s. the severity of a tbi may range from "mild" (i.e. a brief change in mental status or consciousness) to "severe" (i.e. an extended period of unconsciousness or memory loss after the injury). however, most tbi's that occur each year are mild and are commonly called concussions. unfortunately, tbi terminology does not adequately describe the injury or impairment, its treatment, or the resulting outcomes. due to the complexity of the human brain, each person's physiology can result in different patterns of impairment and secondary conditions, requiring different treatment or rehabilitation. the intent of epic clearview™ tbi feasibility (epic-011) is to collect data to further develop the clearview™ response scale to measure electrophysiology associated with tbi

Eligibility criteria:
inclusion criteria: suspected tbi population: 1. acute head trauma within 24-72 hours of presentation 2. 18-65 age inclusive 3. gcs of 3-15 on initial evaluation in ed control population: 1. 18-65 age inclusive 2. gcs score of 15 exclusion criteria: 1. current neurological disease 2. current severe psychological disorder 3. history of substance or alcohol abuse 4. under drug or alcohol influence, if so, must wait at least 24 hrs. prior to consent 5. documented current diagnosis/treatment of cancer (including sickle cell disease) 6. current treatment to the head/brain (radiation, whole brain therapy, gamma knife) 7. head injury in the last two years 8. unwilling to sign informed consent 9. pregnant or potentially pregnant 10. pacemaker, automatic implanted cardiac defibrillator or other implanted electrical device 11. connected to an electronic device that cannot be removed 12. missing all or part of fingers or cuts/burns on pads of fingers 13. long fingernails and unwilling to cut them and keep them cut for the duration of the study 14. hand tremors or involuntary oscillations ("shaking") of the hands that prevents clear imaging additional exclusion criteria for control population: previous head trauma

Keywords: controls
endodontic root-canal treatments evaluated after long-term time

Conditions: Root Canal Treatment; Endodontic Disease

Summary: the aim of the study was to evaluate the root canal treatments performed from 1989 to 1995. type of complication, success, new endodontic diseases and number of success were reported. mean clinical parameters were clinical symptoms and presence/absence of apical radiolucency.

see previous papers (pirani et al., odontology, 2015)

Eligibility criteria:
inclusion criteria: patients affected by endodontic disease and able to attend a recall hygien program exclusion criteria: * sistemic disease cancer inability to attend a recall hygien program

Keywords: endodontology endodontics
efficacy and safety of traditional chinese medicine intervention for women with menopausal syndrome

Conditions: Menopausal Syndrome

Summary: the purpose of this multiple-centered, randomized, controlled study is to investigate the efficacy and safety of a combination using herbs prescription and traditional chinese medicine (tcm) emotion treatment in women with menopausal syndrome.

menopausal syndrome is a high incident disease which is associated with great influence in women's health and quality of life. it involves physical discomforts and emotional symptoms. traditional chinese medicine (tcm) theory emphasizes treating physical and emotional symptoms simultaneously viewing one person as an entirety. herbs prescription and tcm emotion treatment is effective and safe to treat women with menopausal syndrome in clinical practice.

Eligibility criteria:
inclusion criteria: * aged 41-60; * amenorrhea for at least 6 months; * menstruation dysfunction or cessation because of age or bilateral ovariectomy; * hot flushes and night sweats symptoms; * vaginal secretion decreased with or without dyspareunia; * kupperman index (ki) score ≥ 15; * self-rating anxiety scale or self-rating depression scale standard score \>50,but \<72(standard score= scale score ×1.25); * fsh ≥ 20 iu/l; * thickness of endometrium ≤0.5cm if amenorrhea for at least 12 months;or ≤1.5cm if amenorrhea for 6 months to 12 months; * meet the diagnosis criteria of tcm syndrome of liver stagnation and kidney deficiency. exclusion criteria: * with malignant tumor in reproductive system; * with benign tumor in reproductive system and need surgery; * malignant tumor in mammary gland; * irregular vaginal bleeding for unknown reasons; * thickness of endometrium ≥1.5cm by ultrasound examination; * have used sex hormone medicine or joined other clinical trials 3 months before; * allergy; * severe diseases (eg., of the cardiovascular, liver, kidney) or uncontrolled endocrine diseases (eg., diabetes mellitus, hyperthyreosis ) * severe psychiatric disease diagnosed by psychiatric physician; * refuse informed consent.

Keywords: menopausal syndrome tcm intervention